Please assess the completion status of the following clinical trial:

Trial Title: Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male and female adult patients at least 18 years of age on day of signing informed consent~* Histologically confirmed non-small cell lung cancer (NSCLC) adenocarcinoma~* Advanced (stage IIIb) disease that is not amenable to curative intent treatment with concurrent chemoradiation and metastatic (stage IV) patients~* Progressed clinically and/or radiographically per RECIST v1.1 after receiving a PD-1 or PD-L1 antagonist for a minimum of 12 weeks~* Measurable disease per RECIST v1.1~* Disease that can be safely accessed via bronchoscopic, thoracoscopic or percutaneous biopsy for multiple core biopsies and participant is willing to provide tissue from newly obtain biopsies on study in a subgroup of patients~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1~* Adequate organ function~* Highly effective birth control~* Able to swallow and absorb oral tablets~Key Exclusion Criteria:~* Current use of NSAIDs, COX-2 inhibitors~* Known epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS gene alteration~* No history of smoking (≤100 cigarettes lifetime)~* History of severe hypersensitivity reactions to a PD-1/L1 antibody~* Received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment or 5 half-lives, whichever is shorter~* Received prior radiotherapy within 2 weeks of start of study treatment~* Has received a live vaccine within 30 days prior to the first dose of study treatment~* Taking strong CYP3A4 or P-glycoprotein inhibitors or inducers~* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment~* Known additional malignancy that is progressing or has required active treatment within the past 3 years (with some permitted exceptions)~* Known active CNS metastases and/or carcinomatous meningitis~* Active autoimmune disease that has required systemic treatment in past 2 years~* History of pneumonitis that required steroids or has current pneumonitis~* Has an active infection requiring systemic therapy~* Recent or current GI ulcer, colitis or non-immune colitis~* Known history of human immunodeficiency virus (HIV) infection, or known active Hepatitis B, or Hepatitis C virus infection~* Has had an allogeneic tissue/solid organ transplant~* Clinically significant (i.e.active) cardiovascular disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- grapiprant and pembrolizumab combination (Type: EXPERIMENTAL): Participants will be treated with grapiprant in combination with pembrolizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).